AIFA: Riclassificazione del medicinale per uso umano «Vazkepa» (icosapent etile) in classe A (GU Serie Generale n.293 del 14-12-2024)
16/12/2024
Leggi
Leveraging artificial intelligence and machine learning to accelerate discovery of disease-modifying therapies in type 1 diabetes
Shapiro MR, Tallon EM, Brown ME, et al.
Diabetologia. Pub. online 19 Dec 2024.
Leggi
Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis
Teng Y, Fan X, Yu R, Yang X
BMC Endocr Disord. 2024;24(1):278.
Leggi
Effectiveness of semaglutide and tirzepatide in overweight and obese adults with type 1 diabetes
Snell-Bergeon JK, Kaur G, Renner D, et al.
Diabetes Technol Ther. Pub. online 2 Jan 2025.
Leggi
Predicting responsiveness to GLP-1 pathway drugs using real-world data
Zhu X, Fowler MJ, Wells QS, et al.
BMC Endocr Disord. 2024;24(1):269.
Leggi
Hybrid closed-loop insulin therapy and risk of severe hypoglycaemia and diabetic ketoacidosis in young people (aged 2-20 years) with type 1 diabetes: a population-based study
Karges B, Rosenbauer J, Stahl-Pehe A, et al.
Lancet Diabetes Endocrinol. 2024:S2213-8587(24)00284-5.
Leggi
Association between time in tight range and incident diabetic retinopathy in adults with type 2 diabetes
Wang Y, Lu J, Yu J, et al.
Diabetes Obes Metab. Pub. online 18 Dec 2024.
Leggi
SURVEY AMD – UTILIZZO DELLE TECNOLOGIE NEL DT1
Carissimi Soci, una nuova indagine dedicata all’utilizzo delle tecnologie per la gestione dell’adulto con diabete tipo 1, con particolare riferimento ai sistemi con automatismo. Il vostro prezioso contributo ci aiuterà a mappare e comprendere il vissuto dei diabetologi rispetto alle nuove tecnologie e ai sistemi ibridi AHCL. Per rispondere al…
Leggi
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment
Stefan N, Yki-Järvinen H, Neuschwander-Tetri BA
Lancet Diabetes Endocrinol. Pub. online 13 Dec 2024.
Leggi